STAT+: Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion
For Merck, acquiring Prometheus bolsters its research pipeline and introduces new medicines before its blockbuster cancer therapy Keytruda loses patent protection in 2028.
Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline of experimental drugs to treat immune-related diseases.
The deal values Prometheus at $200 per share, or a 75% premium to Friday’s closing stock price. The company went public in March 2021 at $19 per share.
What's Your Reaction?
